Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features
Oliver Bissinger,
Carolin Götz,
Andreas Kolk,
Henning A. Bier,
Abbas Agaimy,
Henning Frenzel,
Sven Perner,
Julika Ribbat-Idel,
Klaus Dietrich Wolff,
Wilko Weichert,
Caroline Mogler
Affiliations
Oliver Bissinger
Department of Oral- and Maxillofacial Surgery, Klinikum rechts der Isar der Technischen Universität München
Carolin Götz
Department of Oral- and Maxillofacial Surgery, Klinikum rechts der Isar der Technischen Universität München
Andreas Kolk
Department of Oral- and Maxillofacial Surgery, Klinikum rechts der Isar der Technischen Universität München
Henning A. Bier
Department of Otolaryngology, Klinikum rechts der Isar der Technischen Universität München
Abbas Agaimy
Institute of Pathology, Erlangen University
Henning Frenzel
Department of Otolaryngology, Luebeck University Hospital
Sven Perner
Department of Pathology, University Medical Center Schleswig-Holstein, Campus Luebeck and Research Center Borstel; Leibniz Center for Medicine and Biosciences
Julika Ribbat-Idel
Department of Pathology, University Medical Center Schleswig-Holstein, Campus Luebeck and Research Center Borstel; Leibniz Center for Medicine and Biosciences
Klaus Dietrich Wolff
Department of Oral- and Maxillofacial Surgery, Klinikum rechts der Isar der Technischen Universität München
Wilko Weichert
Institute of Pathology, Technische Universität München
Caroline Mogler
Institute of Pathology, Technische Universität München
Mammary analogue secretory carcinoma (MASC) is a newly defined entity among salivary gland malignancies which has just been established in the 4th edition of the WHO classification of head and neck tumors. MASC (synonym: secretory carcinoma) are characterized by a specific rearangement of the ETV6 gene locus. Here, we present a series of 3 MASC cases including clinical data with follow-up for up to 26 months. All tumours immunhistochemically displayed strong positivity for cytokeratin 7, and mammaglobin, focal positivity for S100, cytokeratin 5/6 and muc-4. In contrast, immunhistochemical stainings against cytokeratin 14, hormon receptors, Her2/neu, androgen receptor and prostate-specific antigen were consistently negative. FISH analysis showed translocation of the ETV6 gene locus in the majority of tumour cell nuclei. During clinical follow-up, no local relapse or metastasis was detected. As these carcinomas are clinically and radiologically indistinguishable from other salivary gland tumours and as therapeutic approaches and prognosis might differ, we need to be able to diagnose MASC correctly.
